RxSight, Inc. is a commercial-stage medical device company developing light adjustable intraocular lenses (LAL) for cataract surgery. The company's primary product, the RxSight system, comprises a photosensitive intraocular lens and an office-based light delivery device that enables surgeons to customize and refine patients' vision after cataract procedures. The LAL is composed of a special material that changes shape when exposed to ultraviolet light delivered in programmed patterns, allowing post-operative adjustments to correct refractive error and optimize visual acuity without additional surgery.
The RxSight system operates through a two-component workflow: the LAL is implanted during standard cataract surgery, and the light delivery device is used in the ophthalmologist's office to apply targeted UV treatment based on measured visual outcomes. This approach allows personalized vision correction tuned to each patient's post-operative needs. The company generates revenue from the sale of LAL units and light delivery devices to ophthalmic surgical centers and hospitals.
RxSight is headquartered in Aliso Viejo, California, and operates primarily in the United States market. The company was incorporated in Delaware in 1997, originally under the name Calhoun Vision, Inc., before rebranding to RxSight in 2017. With a market capitalization of approximately $400 million, the company remains in the early commercialization phase of its technology deployment.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-0.95 | $-0.95 | -33.8% | |
| 2024 | $-0.71 | $-0.71 | +49.6% | |
| 2023 | $-1.41 | $-1.41 | +41.5% | |
| 2022 | $-2.41 | $-2.41 | +32.5% | |
| 2021 | $-3.57 | $-3.57 | — |